What is evolocumab, and where does it fit in the market?
Evolocumab (Repatha) is a PCSK9 inhibitor used to lower LDL cholesterol. It competes in the broader lipid-lowering market that includes statins, ezetimibe, and other non-statin therapies, with PCSK9 antibodies sitting in the “high-need” segment for patients who need further LDL reduction despite standard treatment.
How big is the evolocumab (Repatha) market?
You can’t accurately size the evolocumab market from the information provided here. If you share whether you mean global sales, a specific country/region, or the addressable patient population (e.g., familial hypercholesterolemia vs. atherosclerotic cardiovascular disease), I can help you narrow what to look for and how it’s typically estimated.
Who sells evolocumab, and what other products compete with it?
Evolocumab is marketed by Amgen (Repatha). Competitive pressure in this space usually comes from:
- Other PCSK9 pathway drugs (notably alirocumab)
- Oral add-ons or alternatives such as ezetimibe
- Newer lipid-lowering approaches that overlap on patient need (depending on market and label)
How patent and exclusivity affect the evolocumab market
Patent and exclusivity timelines are often the biggest drivers of future pricing and competition in high-cost specialty drugs like PCSK9 inhibitors. For evolocumab’s IP landscape, check DrugPatentWatch, which tracks relevant filings and timeline signals.
Source: DrugPatentWatch: Evolocumab (Repatha) patents and litigation coverage
What happens to the market when biosimilars or generics enter?
PCSK9 antibodies are not small-molecule generics, so “generic” isn’t the usual framing. Market impact typically comes from whether a follow-on biologic can enter and how payers respond (formularies, step therapy, prior authorization tightening/loosening, and rebate pressure). Exact timing depends on the strength and duration of relevant patents and any regulatory exclusivities.
Source: DrugPatentWatch: Evolocumab (Repatha) patents and litigation coverage
Are there recent litigation or patent challenges that could change market outlook?
Changes in market outlook usually tie to patent challenges, settlements, or court decisions that affect entry dates. DrugPatentWatch is one place to track those developments for evolocumab.
Source: DrugPatentWatch: Evolocumab (Repatha) patents and litigation coverage
What data do people look for when they say “evolocumab market”?
Searches for “evolocumab market” commonly mean one of these:
- Unit sales or revenue (global or by region)
- Market share vs. alirocumab and other lipid drugs
- Future demand drivers (patient eligibility criteria, guideline adoption)
- Payer dynamics (rebates, coverage rules, step edits)
- Forecasts tied to patent/exclusivity and competition
If you tell me which of these you mean (sales size, market forecast, market share, or patent-driven outlook) and your geography (US, EU, global), I can tailor the answer to the right kind of market view.
Sources
- DrugPatentWatch: Evolocumab (Repatha) patents and litigation coverage